Search
Displaying results 1 - 10 of 20 in total
Ruxolitinib
go.drugbank.com/drugs/DB08877
ApprovedInvestigational
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia ve...
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.
Synonyms: D8-ruxolitinibRuxolitinib Mechanism of Action Action Pathway
smpdb.ca/view/SMP0126971Drug actionRuxolitinib is a selective and potent inhibitor of JAK2 and JAK1, with some affinity against JAK3 and TYK2. … Anticancer effects of ruxolitinib are attributed to its inhibition of JAKs and JAK-mediated phosphorylation of STAT3.
Drugs: RuxolitinibPost-essential Thrombocythemia Myelofibrosis (Post-ET MF)
go.drugbank.com/conditions/DBCOND0069581Drugs: RuxolitinibIntermediate risk Myelofibrosis
go.drugbank.com/conditions/DBCOND0023486Acute Graft-Versus-Host Disease (GVHD)
go.drugbank.com/conditions/DBCOND0125377